Abstract 1413P
Background
The phase 2 LUMINOSITY trial (NCT03539536) of Teliso-V monotherapy has shown acceptable safety & promising efficacy in previously treated patients (pts) with c-Met OE, EGFR WT, NSq NSCLC. Interim PRO data are reported.
Methods
Pts received Teliso-V (1.9 mg/kg) Q2W. PROs were assessed using the European Organisation for Research and Treatment of Cancer quality of life (QOL) questionnaires in lung cancer (LC13) & palliative cancer care (C15-PAL). Time to deterioration (TTD) beyond meaningful change threshold (MCT; ≥10 points from baseline) & mean change from baseline (mCFB) were analyzed.
Results
59 pts were evaluated. Median no. of prior therapies was 1 (range 1–3); median follow-up was 81 d. The table shows median TTD. For cough, pain in chest, pain in other parts, & QOL domains where median TTD was not reached, mCFB analyses revealed initial trends toward improvement. Cough, pain in chest, & overall QOL improved beyond MCT in wk 41, 49, & 41, respectively; pain in other parts trended toward deterioration. mCFB analyses revealed trends toward improvement for the LC13 symptom of hemoptysis, and for alopecia, sore mouth. Peripheral neuropathy deteriorated beyond MCT; dysphagia showed no consistent time trend. For C15-PAL, mCFB trend improved for nausea and vomiting, dyspnea (improved beyond MCT in wk 41), pain, fatigue, emotional function, and insomnia over a sustained duration for ≥29 wk, then deteriorated. Appetite loss worsened initially but improved in wk 41. Constipation improved initially then trended toward deterioration in wk 41 & 45.
Conclusions
This interim analysis suggests extended TTD and trends toward improvement from baseline in key lung cancer symptoms, physical functioning, & QOL; and deterioration in peripheral neuropathy. Impact of Teliso-V monotherapy on PROs will also be assessed at LUMINOSITY trial conclusion and in the phase 3, TeliMET NSCLC-01 trial (NCT04928846). Table: 1413P
Time to deterioration in symptoms, functional domains, and QOL
Instrument | Domains | Event/N | Median TTD, wk (95% CI) |
LC13 | Cough | 7/59 | NR |
Dyspnea | 22/59 | 33 (12, NE) | |
Pain in chest | 9/59 | NR | |
Pain in arm/shoulder | 22/59 | 20 (12, 34) | |
Pain in other parts | 17/59 | NR | |
C15-PAL | QOL | 18/59 | NR |
Physical function | 20/59 | 43 (8, NE) |
NE, not estimable; NR, Kaplan-Meier curve did not reach 50%.
Clinical trial identification
NCT03539536.
Editorial acknowledgement
Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie.
Disclosure
S. Lu: Financial Interests, Institutional, Research Grant: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, Hansoh; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Hansoh; Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co, Roche; Financial Interests, Institutional, Advisory Board: AstraZeneca, Roche, Mirati Therapeutics. J. Bar: Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Institutional, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. N. Girard: Financial Interests, Institutional, Research Grant: AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sivan, Trizell; Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Myers Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, Sivan; Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Leadership Role: International Thymic Malignancy Interest Group; Financial Interests, Personal, Other: AstraZeneca. Q. Xu, R. Sen, C. Ratajczak, S. Ng, S. Xia: Financial Interests, Institutional, Full or part-time Employment: AbbVie. D.R. Camidge: Financial Interests, Institutional, Speaker, Consultant, Advisor: AbbVie, Amgen, Astellas BioPharma, AnHeart Therapeutics, Apollomics, AstraZeneca, BeiGene, Bio-Thera, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, EMD Serono, GSK, Helsinn Therapeutics, Hengrui Pharmaceutical, Janssen, Kestrel Labs, Lilly, Mersana, Nuvalent, Inc., OnKure, Pfizer, Puma Biotechnology, Qilu Pharmaceutical, Ribon Therapeutics, Roche, Sanofi, Seattle Genetics, Takeda, Turning Point Therapeutics; Financial Interests, Institutional, Research Funding: Inivata (Inst).
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20